BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) an international biopharmaceutical company, today announced that its wholly owned subsidiary, Sucampo Pharma Americas, Inc., has completed enrollment of its phase 2 clinical trial of cobiprostone designed to evaluate the compound’s efficacy and safety for the prevention of ulcers and other gastrointestinal injuries in arthritis patients treated with non-steroidal anti-inflammatory drugs (NSAID).
